WeTrials
Recruiting

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Optune® (TTFields, 200 kHz) Concomitant With Maintenance Temozolomide and Pembrolizumab Versus Optune® Concomitant With Maintenance Temozolomide and Placebo for the Treatment of Newly Diagnosed Glioblastoma (EF-41/KEYNOTE D58).

What is this study?

This study is testing whether adding an immunotherapy medicine called pembrolizumab to standard treatments can help patients with a fast-growing brain tumor called glioblastoma. Researchers want to see if this combination, along with a wearable medical device that uses gentle electric fields, helps patients live longer.

Who can participate?

You might be able to join if you are 18 or older, have been newly diagnosed with glioblastoma, and have already finished your initial surgery, radiation, and chemotherapy. There are some rules about previous treatments and medications, such as steroid use, which the study team can help review with you.

What will happen?

Participants will use the wearable Optune device and take standard chemotherapy, along with either the study immunotherapy medicine or a placebo which looks like the medicine but has no active ingredients. The study team will closely monitor your health and how well you tolerate the treatments.

Where and when?

This study is currently recruiting participants at multiple locations, including study sites in Phoenix, Arizona, and Los Angeles and Newport Beach, California.

Key Points
  • 1Testing a new combination treatment for newly diagnosed glioblastoma.
  • 2Compares an immunotherapy medication plus a placebo against the immunotherapy itself.
  • 3Involves using the wearable Optune device and taking standard chemotherapy.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Glioblastoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.